FALSE0001447028701 Veterans CircleWarminsterPennsylvania00014470282020-08-062020-08-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 7, 2020
 
Arbutus Biopharma Corporation
(Exact name of registrant as specified in charter)
 
British Columbia, Canada   001-34949   98-0597776
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)
 
701 Veterans Circle
Warminster, Pennsylvania
  18974
(Address of principal executive offices)   (Zip Code)
 
(267) 469-0914
Registrant’s telephone number, including area code
 
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, without par value   ABUS   The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o




Item 2.02.  Results of Operations and Financial Condition.

On August 7, 2020, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2020 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto.


Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit Number   Description
   
99.1  
104 Cover page interactive data file (formatted as inline XBRL).




SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  Arbutus Biopharma Corporation
   
Date: August 7, 2020 By: /s/ David C. Hastings
  Name: David C. Hastings
  Title: Chief Financial Officer


Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Arbutus Biopharma Charts.
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Arbutus Biopharma Charts.